Verici Dx plc announced it has been granted CPT® Proprietary Laboratory Analyses ("PLA") codes1,2 for both its Clarava and Tuteva tests by the American Medical Association ("AMA"). The new codes have been approved and published by the AMA Editorial Panel and are scheduled to become effective on April 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.75 GBX | -1.46% |
|
+3.85% | -30.77% |
Jul. 16 | Transcript : Verici Dx plc, Q2 2024 Earnings Call, Jul 16, 2024 | |
Jul. 15 | EARNINGS AND TRADING: Genedrive in FDA boost; Bango revenue rises | AN |
![Consensus](/images/consensus_flch.gif)
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-30.77% | 21.52M | |
-6.61% | 12.07B | |
+96.15% | 8.2B | |
-18.38% | 6.59B | |
+9.13% | 5.89B | |
-21.66% | 3.47B | |
+5.36% | 2.52B | |
+41.54% | 2.48B | |
+17.72% | 2.3B | |
-18.43% | 1.58B |
- Stock Market
- Equities
- VRCI Stock
- News Verici Dx plc
- American Medical Association grants Verici Dx two CPT® Codes